Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CAR T cell therapy: looking back and looking forward.
Davila ML, Brentjens RJ. Davila ML, et al. Among authors: brentjens rj. Nat Cancer. 2022 Dec;3(12):1418-1419. doi: 10.1038/s43018-022-00484-w. Nat Cancer. 2022. PMID: 36539498 No abstract available.
GPRC5D-Targeted CAR T Cells for Myeloma. Reply.
Mailankody S, Brentjens RJ, Smith EL. Mailankody S, et al. Among authors: brentjens rj. N Engl J Med. 2022 Dec 15;387(24):2296. doi: 10.1056/NEJMc2213985. N Engl J Med. 2022. PMID: 36516098 No abstract available.
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.
Park JH, Nath K, Devlin SM, Sauter CS, Palomba ML, Shah G, Dahi P, Lin RJ, Scordo M, Perales MA, Shouval R, Tomas AA, Cathcart E, Mead E, Santomasso B, Holodny A, Brentjens RJ, Riviere I, Sadelain M. Park JH, et al. Among authors: brentjens rj. Nat Med. 2023 Jul;29(7):1710-1717. doi: 10.1038/s41591-023-02404-6. Epub 2023 Jul 3. Nat Med. 2023. PMID: 37400640 Free PMC article. Clinical Trial.
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis.
Jurgens EM, Firestone RS, Chaudhari J, Hosszu K, Devlin SM, Shah UA, Landa J, McAvoy DP, Lesokhin AM, Korde N, Hassoun H, Tan CR, Hultcrantz M, Shah GL, Landau HJ, Chung DJ, Scordo M, Eren OC, Dogan A, Giralt SA, Park JH, Rivière I, Brentjens RJ, Smith EL, Wang X, Usmani SZ, Mailankody S. Jurgens EM, et al. Among authors: brentjens rj. J Clin Oncol. 2024 Dec 4:JCO2401785. doi: 10.1200/JCO-24-01785. Online ahead of print. J Clin Oncol. 2024. PMID: 39631041
TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models.
Hackett CS, Hirschhorn D, Tang MS, Purdon TJ, Marouf Y, Piersigilli A, Agaram NP, Liu C, Schad SE, de Stanchina E, Rafiq S, Monette S, Wolchok JD, Merghoub T, Brentjens RJ. Hackett CS, et al. Among authors: brentjens rj. Mol Ther Oncol. 2024 Aug 22;32(3):200862. doi: 10.1016/j.omton.2024.200862. eCollection 2024 Sep 19. Mol Ther Oncol. 2024. PMID: 39308793 Free PMC article.
Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M. Smith M, et al. Among authors: brentjens rj. Nat Med. 2023 Nov;29(11):2954. doi: 10.1038/s41591-022-02069-7. Nat Med. 2023. PMID: 36253610 Free PMC article. No abstract available.
155 results